Heart Failure Clinical Trial

Implantation of the HeartMate 3 in Subjects With Heart Failure Using Surgical SWIFT HM3 PMS

Summary

This is a prospective, post-market, multi-center, non-blinded, single arm study of the HeartMate 3 Left Ventricular Assist System (LVAS). The objective of this study is to evaluate the implantation of the HM3 utilizing techniques other than full median sternotomy (e.g. thoracotomy) and impact on post-implant length of stay.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

Subject or Legal Representative has provided written informed consent by signing the study Informed Consent Form (ICF)
Subject must be ≥ 18 years of age at the time of informed consent
Subject is receiving the HM3 as their first LVAD
Body surface area (BSA) ≥ 1.2m2
Subject is NYHA Class III with dyspnea upon mild physical activity or NYHA Class IV
LVEF ≤ 25%

Subject is:

Inotrope dependent OR

Has CI<2.2 L/min/m2, while not on inotropes and meets one of the following criteria:

On optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and is failing to respond to therapy
Advanced heart failure for at least 14 days AND dependent on intra-aortic balloon pump (IABP) for at least 7 days
Females of child bearing age must agree to use adequate contraception

Exclusion Criteria

Subject has a planned concomitant procedure at time of implant (e.g. valve repair, CABG, ASD repair, etc)
Subject has greater than mild aortic insufficiency
Physiologically significant (i.e. requires intervention) atrial septal defect
Subject has severe right heart failure (RHF) (refer to Appendix 2 for guidance)
Subject has planned Bi-VAD support prior to enrollment
Presence of mechanical aortic valve that will not be either converted to bioprosthesis or oversewn at the time of LVAD implant
Subject has ongoing mechanical circulatory support (MCS) at the time of LVAD surgery other than IABP
Subject has a history of any organ transplant
Positive pregnancy test
Etiology of heart failure (HF) due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis or restrictive cardiomyopathy
Technical obstacles which pose an inordinately high surgical risk, in the judgment of the investigator
Platelet count < 100,000 x 103/L (< 100,000/ml)
Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management
History of confirmed, untreated AAA > 5 cm in diameter within 6 months of enrollment
Presence of an active, uncontrolled infection
Intolerance to anticoagulant or antiplatelet therapies or any other peri/post-operative therapy the investigator will require based upon the subjects' health status

Presence of any one of the following risk factors for indications of severe end organ dysfunction or failure:

An INR ≥ 2.0 not due to anticoagulation therapy
Total bilirubin > 43 μmol/L (2.5 mg/dl) or biopsy-proven liver cirrhosis
History of severe chronic obstructive pulmonary disease (COPD) defined by FEV1/FVC < 0.7, and FEV1 <50% predicted
Fixed pulmonary hypertension with most recent PVR ≥ 8 Wood units that is unresponsive to pharmacologic intervention
History of stroke within 90 days prior to enrollment, or a history of cerebrovascular disease with significant (> 80%) uncorrected carotid stenosis
Serum creatinine ≥ 221 μmol/L (2.5 mg/dl) or the need for chronic renal replacement therapy
Significant peripheral vascular disease (PVD) accompanied by rest pain or extremity ulceration
Pre-albumin < 150mg/liter (15 mg/dl) or albumin <30 g/liter (3g/dl) (if only one available); pre-albumin <150mg/liter (15 mg/dl) and albumin <30 g/liter (3 g/dl) (if both available)
Subject has known hypo- or hyper-coagulable states such as disseminated intravascular coagulation and heparin-induced thrombocytopenia
Participation in any other clinical investigation that is likely to confound study results or affect the study

Study is for people with:

Heart Failure

Estimated Enrollment:

102

Study ID:

NCT04548128

Recruitment Status:

Completed

Sponsor:

Abbott Medical Devices

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 32 Locations for this study

See Locations Near You

Baptist Health Medical Center
Little Rock Arkansas, 72205, United States
Stanford University Medical Center
Palo Alto California, 94304, United States
University of Coloardo Hospital
Aurora Colorado, 80045, United States
Washington Hospital Center
Washington District of Columbia, 20010, United States
Shands at the University of Florida
Gainesville Florida, 32610, United States
AdventHealth Orlando
Orlando Florida, 32803, United States
Emory University Hospital
Atlanta Georgia, 30322, United States
Northwestern Memorial Hospital
Chicago Illinois, 60611, United States
St. Vincent Medical Group
Indianapolis Indiana, 46260, United States
Kansas University Medical Center
Kansas City Kansas, 66106, United States
Ochsner Medical Center
New Orleans Louisiana, 70121, United States
Tufts Medical Center
Boston Massachusetts, 02111, United States
Spectrum Health Butterworth Hospital
Grand Rapids Michigan, 49503, United States
Minneapolis Heart Institute
Minneapolis Minnesota, 55407, United States
University of Minnesota Medical Center Fairview
Minneapolis Minnesota, 55455, United States
Barnes-Jewish Hospital
Saint Louis Missouri, 63110, United States
University of Nebraska Medical Center
Omaha Nebraska, 68198, United States
Mount Sinai Hosptial
New York New York, 10029, United States
New York-Presbyterian/Columbia University Medical Center
New York New York, 10032, United States
University of Rochester Medical Center
Rochester New York, 14642, United States
Duke University Medical Center
Durham North Carolina, 27705, United States
Ohio State University
Columbus Ohio, 43210, United States
Integris Baptist Medical Center
Oklahoma City Oklahoma, 73112, United States
Penn State Milton S. Hershey Medical Center
Hershey Pennsylvania, 17033, United States
Hospital of the University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States
Medical College of South Carolina
Charleston South Carolina, 29425, United States
Cardiothoracic & Vascular Surgeons
Austin Texas, 78756, United States
University of Texas Southwestern Medical Center at Dallas
Dallas Texas, 75390, United States
Methodist Healthcare System of San Antonio
San Antonio Texas, 78201, United States
Sacred Heart Medical Center
Spokane Washington, 99202, United States
University of Wisconsin
Madison Wisconsin, 53792, United States
Foothills Medical Centre
Calgary Alberta, T2N 2, Canada

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Estimated Enrollment:

102

Study ID:

NCT04548128

Recruitment Status:

Completed

Sponsor:


Abbott Medical Devices

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.